Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo

NCT04052425 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT04052425
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04052425 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo
Lead sponsor
Incyte Corporation
Phase
Phase 3
Overall status
Completed
Start date
September 20, 2019
Completion date
October 21, 2021
Enrollment
330 (actual)
Sites
57

Conditions

As the registry lists them; a condition with its own page is linked.

non-segmental vitiligo